# Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

> **NCT03520231** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 6 (actual)

## Conditions studied

- Urothelial Carcinoma
- Kidney Cancer
- Ureter Cancer
- Bladder Cancer

## Interventions

- **DRUG:** Denosumab
- **OTHER:** Denosumab Placebo
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DIETARY_SUPPLEMENT:** Calcium
- **DIETARY_SUPPLEMENT:** Vitamin D

## Key facts

- **NCT ID:** NCT03520231
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-04
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2021-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520231, "Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03520231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*